What is BergaMet NA?
BergaMet North America operates as a premier provider of high-quality Calabrian citrus bergamot supplements, catering to a demographic increasingly focused on preventative health. The company distinguishes itself through advanced formulations that target critical physiological markers, including cardiovascular health, cholesterol management, and metabolic balance. By prioritizing purity and potency, BergaMet NA has carved out a specialized niche, offering natural, science-driven alternatives for individuals seeking to optimize their long-term wellness, healthy aging, and metabolic performance.
How much funding has BergaMet NA raised?
BergaMet NA has raised a total of $39K across 1 funding round:
Debt
$39K
Debt (2021): $39K with participation from PPP
Key Investors in BergaMet NA
PPP
Public-Private Partnership
What's next for BergaMet NA?
With the infusion of this recent financing, BergaMet NA is poised to accelerate its strategic initiatives, likely focusing on market penetration and product line diversification. As the company transitions through its current Series B/C stage, the focus will shift toward scaling distribution channels and enhancing research and development efforts to maintain its competitive edge. The capital will serve as a catalyst for broader consumer reach, enabling the firm to meet the rising demand for evidence-based natural supplements while reinforcing its commitment to clinical-grade efficacy in the wellness sector.
See full BergaMet NA company page
